To the Editor Shaker and Greenhawt reported that stock epinephrine programs in schools yield societal benefits of $270 000 per quality-adjusted life-year (QALY); however, their analysis may contain methodologic errors that threaten its validity.1 Using the authors’ reported values, I have recalculated stock epinephrine’s cost-effectiveness per life saved and QALY gained using a deterministic model avoiding the unnecessary complexity of their Markov microsimulation.
Gerald JK. Benefits of Stock Epinephrine Likely Misestimated. JAMA Pediatr. Published online June 10, 2019. doi:10.1001/jamapediatrics.2019.1530
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: